Nanomedicine Market Top Companies Analysis To growing at CAGR of 12.6% by 2023
Pune, Maharashtra, India, September 14 2020 (Wiredrelease) Allied Analytics –:UPDATE AVAILABLE ON-DEMAND
The research report published by Allied Market Report states that the global nanomedicine market is estimated to reach $261,063 million by 2023. The report provides an in-depth analysis of growth factors, opportunities, market trends, key segments, and competitive landscape. Current market conditions and the future scenario of various regions have been analyzed in the report to help market players in devising expansion strategies. Moreover, it includes country-wise analysis of each region. Product portfolio and business segments of leading market players outline the competitive scenario. The report provides insights to help investors, stakeholders, and new entrants to determine potential opportunities and tap on them to gain competitive advantage. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.
Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.
To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/2021
The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.
The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.
The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.
In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.
Inquire Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2021
The Major Key Players Are:
• Abbott Laboratories
• CombiMatrix Corporation
• General Electric Company
• Sigma-Tau Pharmaceuticals, Inc.
• Johnson & Johnson
• Mallinckrodt plc
• Merck & Company, Inc.
• Nanosphere, Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
The Other Prominent Players Are:
• Celgene Corporation
• UCB (Union Chimique Belge) S.A.
• AMAG Pharmaceuticals
• Nanospectra Biosciences, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Leadiant Biosciences, Inc.
• Epeius Biotechnologies Corporation
• Cytimmune Sciences, Inc.
Key Findings of the Nanomedicine Market:
• The regenerative medicine segment is anticipated to grow at the highest CAGR of 13.8% during the forecast period.
• The U.S. was the major shareholder in the North America nanomedicine market in 2016.
• The oncological diseases segment accounted for one-third share in the global market in 2016, and is expected to maintain this trend throughout the forecast period.
• China occupied one-third share of the Asia-Pacific nanomedicine market in 2016, registering a CAGR of 14.3% from 2017 to 2023.
• The treatment segment dominated the market with about fourth-sevenths of the overall share of the market in 2016.
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.